


CHC YEARBOOK

2020



THE ESSENTIAL GUIDE IN TODAY'S CHALLENGING MARKETS



Nicholas Hall & Company

35 Alexandra Street
Southend-on-Sea SS1 1BW, UK

Tel +44 (0) 1702 220 200

This report may not be reproduced in any form or for any purpose without prior knowledge and consent of the publisher.

The information in this report is believed to be correct at the time of publication. However, no responsibility can be accepted by the publisher for its completeness or accuracy. If you would like clarification of any information in this report, or would like to point out any inaccuracies or omissions, please contact:

Ian Crook

Managing Editor, Reports

e-mail: ian.crook@NicholasHall.com

For information on other products and services provided by Nicholas Hall & Company, or for additional copies of this report, please contact:

Melissa Lee

COO, Marketing

e-mail: melissa.lee@NicholasHall.com

CHC YearBook 2020
Published by Nicholas Hall's Reports
April 2020

© **Nicholas Hall & Company Guernsey**

**Nicholas Hall's Reports™® is a registered
trademark belonging to Nicholas Hall**

Contents

CHC Market Definition	VIII
1. Global Review	1
World Overview	1
Competitive Landscape	3
Switch	4
Brands & Innovation	5
Retailing	6
Outlook	7
2. Regional Review	11
North America	11
East & South East Asia	13
Western Europe	15
Central & Eastern Europe	17
Japan	19
Latin America	21
Indian Subcontinent	23
Australasia	25
3. Leading Markets	27
USA	28
China	30
Japan	32
Germany	34
Russia	36
France	38
Italy	40
Brazil	42
India	44
UK	46
Canada	48

Poland	50
Australia	52
South Korea	54
Spain	56
4. Category Review	58
Analgesics	58
Cough, cold & allergy	60
Gastrointestinals	62
Vitamins, minerals & supplements	64
Dermatologicals	66
Lifestyle CHC	68
5. Leading Companies	70
GlaxoSmithKline	74
Johnson & Johnson	75
Bayer	76
Sanofi	77
RB	78
Procter & Gamble	79
Taisho	80
China Resources 999	81
Takeda	82
Teva	83
Stada	84
Mondelez	85
Prestige Consumer Healthcare	86
The Nature's Bounty Company	87
Otsuka	88
Bausch Health	89
Abbott	90
Mylan	91
Perrigo	92
Novartis	93

6. Mergers & Acquisitions	94
7. Leading Brands	115
Vicks	123
Tylenol	124
Advil	125
Halls	126
Voltaren	127
Centrum	128
Nature Made	129
Panadol	130
Nicorette	131
Mucinex	132
Claritin	132
Nurofen	133
Nature's Bounty	134
Strepsils	135
Zyrtec	136
Lipovitan	136
Bayer Aspirin	137
Allegra	138
Dong-e E-Jiao	139
Caltrate	140
Yunnan Baiyao	141
999 Gan Mao Ling	141
Aleve	142
Doliprane	143
Gaviscon	143
8. Hot Topics	145
Coronavirus pandemic	145
CBD	146
Digital marketing	148

9. Rx-to-OTC Switch	151
Overview	151
Western Europe	152
North America	155
Japan	157
Australasia	158
Emerging markets	159
The Big Switches	176
Aleve	177
Allegra	177
Alli, Xenical	177
Claritin	178
Differin	178
ellaOne	179
Flonase / Flixonase	180
Formigran	180
Loxonin S	181
Maloff Protect	182
MiraLAX	182
Mucinex	183
Nasacort	183
Nexium 24HR	184
Plan B, NorLevo, Postinor, Levonelle	184
Prevacid 24HR	185
Prilosec OTC	186
Rhinocort	186
Silvasta, MaxOn Active, Viagra Connect	187
Volini	188
Voltaren	189
Zyrtec	189

10. New Product Development & Innovation	190
Analgesics	191
Cough, cold & allergy	192
Gastrointestinals	193
Vitamins, minerals & supplements	194
Dermatologicals	195
Lifestyle CHC	197
11. Global Retailing	199
Market snapshots	200
Private Labels & Generics	211
The major retail players	212
The Future of Global Retailing	216
12. Company Ownership	217
13. Brands & Marketers	228
14. Manufacturers' Associations	273
15. Glossary	280

Charts

Chart 1: Global CHC sales by region 2019	1
Chart 2: Global CHC sales by category 2019	2
Chart 3: Global CHC forecasts by region	8
Chart 4: Global CHC forecasts by category	9
Chart 5: North America CHC market by category 2019	11
Chart 6: North America leading CHC marketers & brands 2019	12
Chart 7: E&SE Asia CHC market by category 2019	13
Chart 8: E&SE Asia leading CHC marketers & brands 2019	14
Chart 9: Western Europe CHC market by category 2019	15
Chart 10: Western Europe leading CHC marketers & brands 2019	16
Chart 11: C&E Europe CHC market by category 2019	17

Chart 12: C&E Europe leading CHC marketers & brands 2019	18
Chart 13: Japan CHC market by category 2019	19
Chart 14: Japan leading CHC marketers & brands 2019	20
Chart 15: Latin America CHC market by category 2019	21
Chart 16: Latin America leading CHC marketers & brands 2019	22
Chart 17: Indian Subcontinent CHC market by category 2019	23
Chart 18: Indian Subcontinent leading CHC marketers & brands 2019	24
Chart 19: Australasia CHC market by category 2019	25
Chart 20: Australasia leading CHC marketers & brands 2019	26
Chart 21: Global leading 15 CHC markets 2019	27
Chart 22: USA CHC market by category 2019	28
Chart 23: USA leading CHC marketers & brands 2019	28
Chart 24: China CHC market by category 2019	30
Chart 25: China leading CHC marketers & brands 2019	30
Chart 26: Japan CHC market by category 2019	32
Chart 27: Japan leading CHC marketers & brands 2019	32
Chart 28: Germany CHC market by category 2019	34
Chart 29: Germany leading CHC marketers & brands 2019	34
Chart 30: Russia CHC market by category 2019	36
Chart 31: Russia leading CHC marketers & brands 2019	36
Chart 32: France CHC market by category 2019	38
Chart 33: France leading CHC marketers & brands 2019	38
Chart 34: Italy CHC market by category 2019	40
Chart 35: Italy leading CHC marketers & brands 2019	40
Chart 36: Brazil CHC market by category 2019	42
Chart 37: Brazil leading CHC marketers & brands 2019	42
Chart 38: India CHC market by category 2019	44
Chart 39: India leading CHC marketers & brands 2019	44
Chart 40: UK CHC market by category 2019	46
Chart 41: UK leading CHC marketers & brands 2019	46
Chart 42: Canada CHC market by category 2019	48

Chart 43: Canada leading CHC marketers & brands 2019	48
Chart 44: Poland CHC market by category 2019	50
Chart 45: Poland leading CHC marketers & brands 2019	50
Chart 46: Australia CHC market by category 2019	52
Chart 47: Australia leading CHC marketers & brands 2019	52
Chart 48: South Korea CHC market by category 2019	54
Chart 49: South Korea leading CHC marketers & brands 2019	54
Chart 50: Spain CHC market by category 2019	56
Chart 51: Spain leading CHC marketers & brands 2019	56
Chart 52: Global CHC analgesics category split 2019	58
Chart 53: Leading analgesic brands 2019	59
Chart 54: Global CHC CCA category split 2019	60
Chart 55: Leading CCA brands 2019	61
Chart 56: Global CHC GIs category split 2019	62
Chart 57: Leading GI brands 2019	63
Chart 58: Global CHC VMS category split 2019	64
Chart 59: Leading VMS brands 2019	65
Chart 60: Global CHC dermatologicals category split 2019	66
Chart 61: Leading dermatological brands 2019	67
Chart 62: Global lifestyle CHC category split 2019	68
Chart 63: Leading lifestyle CHC brands 2019	69
Chart 64: Top 250 CHC marketers 2019	70
Chart 65: CHC merger, acquisition, alliance & joint-venture activity 2015-2020	94
Chart 66: Multiples paid for CHC acquisitions 2014-2020	114
Chart 67: Leading CHC brands 2019	115
Chart 68: Legal status of ingredients in selected world markets	164
Chart 69: Legal status of ingredients in selected European markets (I)	168
Chart 70: Legal status of ingredients in selected European markets (II)	172
Chart 71: Big Switches global CHC sales 2019	176
Chart 72: Company Ownership Index	217
Chart 73: Brands & Marketers Index	228

CHC Market Definition

Market sizes, growth rates and brand sales are, unless stated otherwise, based on Nicholas Hall & Company's global CHC database, **DB6**. All data is being updated continually, and is believed to be accurate at the time of going to press.

Sales data is for the calendar year January – December for 2015-2019.

Sales data includes all non-prescription sales.

Data includes retail sales in all outlets. Mail order, multi-level, e-commerce and other non-retail sales are not included.

All market data is expressed at manufacturers' sales prices (MSP).

Market data is calculated in local currency and converted to US\$ at the rate that applied on 31 December 2019.

Under-the-counter (UTC) sales are not included except in countries where there are few or no legal OTCs (such as Turkey) where UTC sales are included for products that fall within the DB6 category definition and would be considered consumer items in most established markets.

Non-prescribed sales of semi-ethical brands (which can be sold both with and without a prescription) are included in all sales estimates. Prescription sales of OTC-registered brands are included where these sales are significant.

Sales of traditional medicines (e.g. TCM, jamu and ayurvedic), homeopathic medicines, food supplements and medical devices are included where they are packaged and positioned alongside registered OTCs.

Manufacturers' sales data is based on branded products alone. Manufacturers' sales do not include any private label sales to retailers or bulk sales of unbranded products to other manufacturers or distributors. Sales of private labels are included in "others" in each subcategory.

Sales data for each manufacturer includes sales made by any national or international subsidiaries.

All acquisitions are added to manufacturers' historical data so growth excludes the effect of M&A activity.

Volume sales, where available, represent the absolute number of packs sold (unadjusted for size / dosage).

All forecasts take into account published socio-economic and demographic forecasts plus CHC-specific factors such as switch, regulatory change and historical trends.

DB6 CHC Categories & Subcategories

Analgesics

Systemic analgesics
 Topical analgesics
 Mouth & dental analgesics

Cough, Cold & Allergy

Cough remedies
 Systemic cold & flu
 Topical decongestants
 Systemic decongestants
 Chest rubs & inhalants
 Sore throat remedies & medicated confectionery
 Allergy remedies
 Asthma remedies

Gastrointestinals

Antacids
 Antiflatulents
 Laxatives
 Antidiarrhoeals
 Antinauseants
 Digestive enzymes
 Liver & bile remedies
 Antispasmodics & IBS remedies
 Traditional digestive remedies
 Other gastrointestinals

Vitamins, minerals & supplements

Single vitamins
 Vitamin A
 Vitamin B
 Vitamin C
 Vitamin D

VMS (cont.)

Vitamin E
 Other single vitamins
 Multivitamins
 Pregnancy vitamins
 Minerals
 Calcium
 Iron
 Zinc
 Magnesium
 Fluoride
 Other minerals
 Hair & beauty supplements
 Herbal & natural supplements
 Co-enzyme Q10
 Fish oils & omega 3
 Garlic
 Ginseng
 GLA
 Lecithin
 Royal jelly
 Other herbal & natural supplements
 Herbal memory & brain health
 Herbal antidepressants
 Herbal & natural joint health
 Herbal menopause supplements
 Immune supplements
 Eye health supplements
 Probiotics
 Tonics & cure alls
 OTC tonic drinks
 Chyawanprash

Dermatologicals

- Acne remedies
- Haemorrhoid preparations
- Antifungals
 - General antifungals
 - Nail antifungals
 - VYI treatments
- Anti-itch products
- Wound care
 - Antiseptics & disinfectants
 - Wound healers
- Cold sore treatments
- Scalp treatments
- Lice treatments
- Hair loss treatments
- Wart & verruca treatments
- Circulatory aids
- Lip care

Derma (cont.)

- Feminine intimate care
- Eczema & psoriasis treatments
- Other dermatologicals
- Lifestyle OTCs**
- Smoking control
- Sedatives & sleep aids
- Stimulants
- Eye care
- Ear care
- Urinary products
- Prostate remedies
- Systemic cardiovasculars
- Obesity treatments
- Erectile dysfunction
- Daily oral contraception
- Emergency hormonal contraception
- Other lifestyle OTCs

DB6 Countries

North America

- Canada
- Puerto Rico
- USA

Western Europe

- Austria
- Belgium
- Denmark
- Finland
- France
- Germany

Western Europe (cont.)

- Greece
- Ireland
- Italy
- Netherlands
- Norway
- Portugal
- Spain
- Sweden
- Switzerland
- UK

Latin America

Argentina
 Brazil
 Chile
 Colombia
 Ecuador
 Mexico
 Peru

Central & Eastern Europe

Bulgaria
 Croatia
 Czech Republic
 Hungary
 Lithuania
 Poland
 Romania
 Russia
 Slovakia
 Slovenia
 Ukraine

East & South East Asia

China
 Hong Kong
 Indonesia
 Malaysia
 Philippines

East & South East Asia (cont.)

Singapore
 South Korea
 Taiwan
 Thailand
 Vietnam

Indian Subcontinent

India
 Pakistan

Japan**Australasia**

Australia
 New Zealand

Rest of World

Algeria
 Egypt
 Iran
 Israel
 Kazakhstan
 Morocco
 Nigeria
 Saudi Arabia
 South Africa
 Turkey
 UAE
 Other countries

Contact DB6

For further details of Nicholas Hall's Global CHC Database, **DB6**, please contact the **DB6** team: Tel: +44 (0)1702 220 218
 e-mail: celine.waller@NicholasHall.com

Central & Eastern Europe

- Population 2019: 288.5mn
- OTC sales per capita 2019: \$41.20

Chart 11: C&E Europe CHC market by category 2019

Category	\$mn	19/18	% share
Analgesics	1,423	+6%	12
Cough, Cold & Allergy	3,150	+2%	27
Gastrointestinals	1,614	+4%	14
Vitamins, Minerals & Supplements	2,605	+5%	22
Dermatologicals	1,810	+3%	15
Lifestyle CHC	1,283	+6%	11
Total	11,887	+4%	100

Source: Nicholas Hall Reports based on DB6 (MSP)

- Historically dynamic region has seen slowing of topline in recent years; growth in key market Russia is largely driven by price rises
- Economic prosperity via expanding middle class is a major growth driver in some markets, although C&EE still largely comprises diverse markets at different stages of development
- Political and economic instability across the region is reflected in CHC topline, potentially deterring MNC investment (although international players retain a commanding presence)
- Historical economic difficulties are still impacting some nations; currency devaluation hit Russian rouble strongly, political and economic instability are still a challenge and consumers are looking to reduce spending
- Several C&EE countries have joined the EU since 2004 (Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, Slovenia, Bulgaria, Romania and Croatia), allowing for greater standardisation of OTC regulations
- These markets have been affected by EU-wide switches like pantoprazole, and reverse switches such as bufexamac and topical ketoprofen
- Regulatory focus across the region remains on safety and stricter control of medicines, with switch remaining a comparatively low priority, particularly in non-EU markets (although Russia saw limited number of switches in recent years)
- Wide income disparity has led to local players setting prices considerably lower than Western brand leaders, as well as launching cost-effective high-strength and large pack size presentations

Chart 64: Top 250 CHC marketers 2019 (cont.)

Marketer	\$mn	CAGR	Marketer	\$mn	CAGR
183 Sanfer	90	+6%	218 Esteve	69	+3%
184 Orkla Health	88	+6%	219 Il Dong	69	+1%
185 UCB	87	-2%	220 Torrent	69	+13%
186 Nordic Naturals	87	+1%	221 Dermapharm	68	+8%
187 Zhuzhou Qianjin	87	+2%	222 Jingzhu Tibetan	68	+6%
188 Materia Medica	86	+5%	223 Insud Pharma	68	+28%
189 Solinest	86	+4%	224 Mayoly-Spindler	67	-5%
190 Dr Theiss Naturwaren	85	+18%	225 Julphar	67	+7%
191 Sopharma	85	+6%	226 Farmak	67	+12%
192 Cimed	84	+28%	227 Sofar	67	+2%
193 Karo Pharma	83	+0%	228 Yunnan Green A Biotech	67	+5%
194 Chiesi	82	+2%	229 PiLeJe	66	+18%
195 Fidia Farmaceutici	81	+5%	230 Hermes	65	+0%
196 Combe	80	+7%	231 Himalaya	65	+8%
197 Pohl Boskamp	78	+6%	232 Kin Fung	65	+3%
198 NeilMed	78	+7%	233 Hasco Lek	65	+9%
199 Tongyitang	77	+20%	234 ShenQi	65	-13%
200 Cinfa	77	+5%	235 Mankind Pharma	64	+15%
201 Zhejiang Jolly	76	+1%	236 Megalabs	64	+10%
202 CFP	76	-1%	237 AFH	63	+9%
203 CSPC	76	+11%	238 WN Pharmaceuticals	63	+0%
204 Medice	75	+7%	239 Dong Wha	63	+3%
205 Wakunaga	75	-2%	240 Spimaco	63	+2%
206 Guangzhou Xiang Xue	74	-6%	241 Infamed	62	+16%
207 Li Shizhen	74	+8%	242 Haw Par Healthcare	62	+15%
208 Emcure	73	+14%	243 Hubei Wushi	62	+1%
209 Eos Products	73	-8%	244 Shiseido	62	+0%
210 Wuhan Jianmin	72	+4%	245 Akorn	60	+7%
211 Cipla	72	+11%	246 Jilin Aodong	60	-1%
212 Woerwag	71	+13%	247 Sino Biopharm	59	+24%
213 Leo Pharma	70	+2%	248 Chong Kun Dang	59	+10%
214 Meiji Seika Kaisha	70	+1%	249 Centek	59	+6%
215 Shionogi Healthcare	70	+0%	250 Guangxi Bangqi	59	+27%
216 Eurofarma	69	+25%			
217 Orthomol	69	+0%	Top 250 Total	84,120	+4%

CAGR refers to period 2015-19

Source: Nicholas Hall Reports based on **DB6** (MSP)

Stada

Core business: Pharmaceuticals

Website: www.stada.com

Head office: Stadastraße 2-18,
61118 Bad Vilbel, Germany

Corporate turnover (2019): \$2.9bn (+12%)

Total CHC sales (2019): \$923mn (-1%)

Top CHC brands (2019): Magnyl (\$60mn),
Grippostad (\$41mn), Snup (\$40mn), Nizoral
(\$39mn), Vitaprost (\$24mn), Aqualor (\$22mn)

Principal markets for CHC products

C&E Europe (51% of total sales), Western Europe (46%), Asia-Pacific (1%)

Principal CHC categories & brands

Analgesics (8%): Kamistad, Paracetamol-Stada, Mobilat, Ibuprofen-EG

CCA (23%): Grippostad, Snup, Aqualor, Covonia, Nasen-AL, Xymelin, Lavomax

Gastrointestinals (7%): Essliver, Lactulose-Aliud, Glycerin-Nizhpharm

VMS (19%): Artra, Calcium Nycomed, Vitrum, Proenzi, Biopron, Magnetrans

Dermatologicals (29%): Nizoral, Hirudoid, Cetraben, Zeroderma

Lifestyle CHC (16%): Magnyl, Vitaprost, Hoggar, Urinal, Melaxen, Care

- Stada has entered the global CHC top tier via a series of acquisitions; in 2018 it announced plans to “realign” the company into three pillars (non-prescription OTC products, generics and specialty pharmaceuticals)
- 2020 saw restructuring in Austria, dividing the company into distinct Consumer Healthcare and Prescription Medicines arms there
- In 2019 it claimed it was “very selective” on M&A activity, and its acquisition strategy has proved effective in building scale in Europe (it is CHC No.3 in C&E Europe)
- 2018-19 it acquired marketing rights to Nizoral in Europe, the Middle East and Africa, several brands from Takeda and GSK, as well as Ukrainian company Biopharma
- Acquisition of Takeda brands made it the largest foreign investor in Russia’s pharma industry
- Purchase of Walmark and a further portfolio of 15 established consumer health brands from GSK in 2020 secured its place as a top-tier CHC marketer
- Presence in Asia-Pacific boosted by 2020 acquisition of FERN C vitamin C-based nutritional range in Philippines

- Canada is brand's No.3 market after continued growth since 2009 launch; switch to mass-market status of small pack sizes in 2010 and rollout of nighttime presentation in 2016 benefited sales
- Aleve's largest other markets are in Latin America
- In Mexico Aleve (known as Flanax) differentiates from rivals with indication for muscular pain; launched Flanax Nocto (Aleve PM equivalent) in 2017

Doliprane (Sanofi)

- Only sold in France (generates over 90% of total sales), Algeria and Morocco, paracetamol-based Doliprane ranks 6th among systemic analgesics worldwide
- The majority of versions are semi-ethical and reimbursed at 65%; brand's steady sales show the importance of reimbursed status to consumers
- To support brand among pharmacists, Sanofi offers training courses – distance learning or evening classes – on pain management issues
- Growth driven by high-strength paracetamol 1g presentations, boosted by ongoing trade ads
- France's reverse-switch of codeine in July 2017 saw line extension Codoliprane (codeine, paracetamol) become Rx
- A pure OTC range launched in 2015, comprising Doliprane Caps 1,000mg, Doliprane Tabs 1,000mg and 500mg, Doliprane Orodoz, Doliprane Vitamine C, Doliprane Codeine and paediatric syrups Doliprane Liquiz 200mg and 300mg, most of which are available for self-selection
- TV ads in 2018 focused on promoting Doliprane Liquiz and Doliprane Caps, with ads ending with the tagline, "Because all pain counts"
- Online promotion includes contreladoleur.fr, an online platform designed to provide information and support for consumers suffering from chronic pain
- Doliprane range includes cold & flu presentations under the Dolirhume name (No.7 position in France's systemic cold & flu category), backed with TV ads featuring a superhero who effectively relieves cold & flu symptoms

Gaviscon (RB)

- Present in over 40 markets worldwide (owned and marketed by RB in almost all), Gaviscon is the No.1 OTC antacid globally and leads the traditional antacids segment; its strong presence across numerous countries is a result of RB's creation of a strong and unified international image

8. Hot Topics

Coronavirus pandemic

- SARS-CoV-2 is a novel coronavirus, causing the disease Covid-19; it originated in Wuhan, China in December 2019 but subsequently spread worldwide within three months
- On 11th March 2020 WHO declared the outbreak a pandemic
- As of 27th April the virus is known to have infected nearly 3mn people and killed more than 200,000
- SARS-CoV-2 has proved difficult to contain as sufferers are contagious but asymptomatic during early incubation period, making it harder to identify and quarantine those infected
- The rapid spread is having an increasing impact on economies, industries and businesses worldwide
- Supply and demand for crucial medicines has been impacted; China reportedly makes over 150 crucial drugs, including blood pressure pills, and produces roughly 40% of the pharma industry's active ingredients
- Key OTCs and supplements whose supply will be affected include paracetamol, ibuprofen and vitamins
- Leading pharma players will likely be able to limit effects of supply problems in the short term, but longer-term issues may lead to shortages
- As person-to-person transmission within infected communities increases and government policies change, it will affect where people go to seek treatment (hospital vs pharmacy) and what treatment is given (Rx vs OTC)
- With only mild symptoms reported in around 80% of cases, official advice in many countries may be for otherwise healthy adults to self-isolate and treat with OTCs
- Yet in developing countries the high proportion of vulnerable individuals suffering immunocompromising diseases (HIV, chronic malnutrition) may see more people suffer severely
- Impact on the CHC market is already becoming apparent with sales of antiseptics & disinfectants, antibacterial hand gels, face masks, immune-boosting supplements and OTC antivirals all seeing significant upturn in sales
- Beiersdorf ramped up production of medical grade disinfectants in its European production network, L'Oréal increased mass production of its La Roche Posay hand sanitiser, while Pierre Fabre reconfigured a shampoo production line at one of its French factories to start producing a hydro-alcoholic gel
- Meanwhile, pharma players including J&J, GSK and Sanofi are working fast to develop a vaccine

Chart 69: Legal status of ingredients in selected European markets (I)

	Belgium	France	Germany	Italy	Spain	UK
Allergy / Asthma remedies						
acrivastine	U	U	Rx	U	U	M
azelastine	P	P	P	P	Rx	Rx
beclometasone (nasal)	Rx	P	P	P	P	M
budesonide (nasal)	Rx	Rx	Rx	Rx	Rx	Rx
cetirizine	P	P	P	P	P	M
clemastine	U	U	P	U	U	P
dexchlorpheniramine	P	P	U	P	P	Rx
fexofenadine	P	Rx	Rx	P	P	Rx
fluticasone	P	Rx	P	Rx	P	M
ketotifen	Rx	Rx	P	P	Rx	Rx
levocabastine	P	P	P	P	P	P
levocetirizine	P	Rx	Rx	Rx	Rx	Rx
loratadine	P	P	P	P	P	P
meclozine	P	P	Rx	U	P	P
mometasone (nasal)	P	Rx	P	Rx	Rx	P
triamcinolone	P	Rx	Rx	Rx	P	P

continued

Chart 73: Brands & Marketers Index (cont.)

Brand	Key Category	Countries	Marketer
Tempra	systemic analgesics	Mexico	RB
		Philippines	Taisho
		Indonesia	Taisho
Thealoz	eye care	France	Théa
		Italy	Théa
		Spain	Théa
		Belgium	Théa
		Germany	Théa
		Poland	Théa
TheraFlu	systemic cold & flu, systemic decongestants	USA	GlaxoSmithKline
		Russia	GlaxoSmithKline
		Poland	GlaxoSmithKline
		Switzerland	GlaxoSmithKline
		Hungary	GlaxoSmithKline
		Canada	GlaxoSmithKline
		Romania	GlaxoSmithKline
		Mexico	GlaxoSmithKline
		Kazakhstan	GlaxoSmithKline
		South Korea	GlaxoSmithKline
		Ukraine	GlaxoSmithKline
ThermaCare	topical analgesics	Slovakia	GlaxoSmithKline
		Germany	Angelini
		USA	Pfizer
		Italy	Angelini
		Switzerland	Angelini
Thrive	<i>see Nicotinell</i>	Austria	Angelini
Tiger Balm	topical analgesics	Thailand	Haw Par Healthcare
		China	Xiamen Tiger Medicals/ Haw Par Healthcare
		USA	Prince of Peace
		India	Alkem
		Germany	Queisser

continued